Diabetes agent Metformin was well-tolerated, although it did not improve progression-free survival (PFS) or overall survival (OS) in participants with locally advanced non-small cell lung cancer (NSCLC), according to the results of NRG-LU001 trial.
These results are based on local center reported outcomes. Trial participants will continue to be followed for changes in their status. The initial report of these results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting ...
Diabetes agent Metformin was well-tolerated, although it did not improve progression-free survival (PFS) or overall survival (OS) in participants with locally advanced non-small cell lung cancer (NSCLC), according to the results of NRG-LU001 trial.
These results are based on local center reported outcomes. Trial participants will continue to be followed for changes in their status. The initial report of these results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting ...